Prenatal mTOR Inhibitors in Tuberous Sclerosis Complex: Current Insights and Future Directions
Open Access
- 23 October 2024
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (21) , 6335
Abstract
Background: Tuberous sclerosis complex (TSC) can present prenatally, often with cardiac rhabdomyomas, which, if large, may cause complications such as hydrops fetalis and reduced cardiac output. Prenatal treatment of these lesions with mTOR inhibitors, approved for other TSC manifestations, is under investigation. We hypothesize that mTOR inhibitors could help manage or prevent other TSC-related conditions, particularly neurological issues like epilepsy and CNS lesions, potentially improving neurodevelopmental outcomes. However, the safety of prenatal mTOR treatment remains a concern, especially for foetal development, and limited data are available on neurological outcomes. Methods: We conducted a literature review using PubMed, EMBASE, and Cochrane CENTRAL, focusing on studies involving mTOR inhibitors for prenatal TSC management. The search included case reports and series involving pregnant women diagnosed with TSC or early manifestations like cardiac rhabdomyomas. Keywords included “mTOR Inhibitor”, “Rapamycin”, “tuberous sclerosis complex”, “prenatal”, and “rhabdomyoma”. Results: Three prenatal mouse studies and eight papers reporting on ten pregnant women treated with mTOR inhibitors were identified. Conclusions: The literature confirms that prenatal mTOR inhibitors may reduce cardiac rhabdomyomas. However, further studies are needed to explore their broader potential, particularly in preventing neurological complications, while carefully considering their impact on intrauterine growth and neurodevelopment.Keywords
Funding Information
- Italian Ministry of Health with “Current Research funds”
This publication has 62 references indexed in Scilit:
- Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the EPISTOP TrialAnnals of Neurology, 2020
- Is autism driven by epilepsy in infants with Tuberous Sclerosis Complex?Annals of Clinical and Translational Neurology, 2020
- Fetal cardiac rhabdomyomas treated with maternal sirolimusPrenatal Diagnosis, 2019
- Current concepts on epilepsy management in tuberous sclerosis complexAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2018
- A clinical update on tuberous sclerosis complex‐associated neuropsychiatric disorders (TAND)American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2018
- Everolimus for treatment of tuberous sclerosis complex‐associated neuropsychiatric disordersAnnals of Clinical and Translational Neurology, 2017
- Prenatal diagnosis of giant cardiac rhabdomyoma in tuberous sclerosis complex: a new therapeutic option with everolimusUltrasound in Obstetrics & Gynecology, 2014
- Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complexAnnals of Neurology, 2008
- Natural history and long‐term outcome of cardiac rhabdomyomas detected prenatallyPrenatal Diagnosis, 2004
- Selective alterations in glutamate and GABA receptor subunit mRNA expression in dysplastic neurons and giant cells of cortical tubersAnnals of Neurology, 2001